CD8A and neoplasm: The combination of NHS-muIL12 and avelumab enhances anti-TNBC tumor efficacy and induces the generation of tumor-specific immune memory, augmenting the proliferation of cytotoxic NK and CD8+ T cells, potentially representing a promising approach for the treatment of patients with solid tumors 187.